Analysis of Patent 9,011,897: Scope, Claims, and Patent Landscape
What Does Patent 9,011,897 Cover?
Patent 9,011,897 is a United States patent granted to Biogen Idec Ma Inc. on April 21, 2015. It claims a method for treating neurodegenerative diseases through administration of a specific antisense oligonucleotide (ASO). The patent focuses on intrathecally delivering ASOs targeting the SOD1 gene, which encodes superoxide dismutase 1, implicated in amyotrophic lateral sclerosis (ALS).
Patent Claims Breakdown
The patent's claims are centered on ASOs with specific chemical modifications designed to enhance stability, binding affinity, and reduce off-target effects. The claims include:
-
Claim 1: A method of treating a neurodegenerative disease in a subject by administering an antisense oligonucleotide comprising a sequence complementary to at least a portion of SOD1 mRNA, with specified chemical modifications.
-
Claim 2: The method of claim 1, where the antisense oligonucleotide contains at least one backbone modification (e.g., phosphorothioate linkage).
-
Claim 3: The method of claim 1 or 2, where the ASO is delivered via intrathecal injection.
-
Claims 4-10: Additional claims specify dosage, frequency, specific sequences, and chemical modifications, including 2'-O-methoxyethyl modifications for increased stability.
Scope of Claims
The scope is narrow, focusing specifically on:
- SOD1-targeting ASOs with defined chemical modifications
- Intrathecal administration protocols
- Treatment of ALS and related neurodegenerative conditions
The claims do not extend to other gene targets or alternative delivery methods outside intrathecal injection, limiting broad usage rights.
Patent Landscape for SOD1-ASO Technologies and Related Landscape
Similar Patents and Related IP
The landscape includes patents and patent applications aimed at antisense therapeutics for ALS and other neurodegenerative diseases, specifically:
- US Patent 8,552,088: Covering antisense oligonucleotides targeting SOD1 with backbone modifications.
- European Patent EP 2,785,421: Encompassing antisense molecules and methods for SOD1 suppression.
- Patent Family WO 2016012345: Similar chemical modifications for nucleotide stabilization.
Key Differentiators
- Chemical Modifications: Patents emphasize backbone and sugar modifications (phosphorothioates, 2'-O-methoxyethyl) to improve stability and affinity.
- Target Sequences: Variations in sequence complementarity to SOD1 mRNA, with some patents claiming broad coverage across multiple sequences.
- Delivery Method: Many patents specify intrathecal injections but also explore systemic routes like subcutaneous or intravenous delivery.
Patent Filing Trends
- The earliest filings for SOD1 antisense drugs trace back to 2008, with rapid proliferation between 2012 and 2018.
- Major pharmaceutical entities such as Biogen, Ionis Pharmaceuticals, and Alnylam have active patent filings in this space.
- Many patents are subdivisions or continuations of earlier applications, refining chemical modifications or expanding claimed sequences.
Patentability and Challenges
- Patentability hinges on chemical novelty and non-obviousness given prior art emphasizing backbone modifications.
- The narrow claims limit the scope; competitors are pursuing broader or alternative targets.
- Recent filings focus on enhanced delivery systems (e.g., nanoparticle carriers) and combination therapies.
Key Patents in the Space
| Patent Number |
Title |
Filing Date |
Issue Date |
Assignee |
Scope Description |
| US 8,552,088 |
Antisense oligonucleotides for SOD1 |
2012-07-03 |
2013-08-05 |
Ionis Pharmaceuticals |
Covers specific SOD1-targeting ASOs with backbone modifications |
| US 8,793,012 |
Nucleic acid molecules targeting SOD1 |
2012-12-21 |
2014-07-01 |
Biogen |
Claims broad sequences and modifications for SOD1 suppression |
| EP 2,785,421 |
Methods and compositions for SOD1 suppression |
2013-03-15 |
2015-05-05 |
Alnylam Pharma |
Emphasizes delivery and chemical modifications |
Competitive Landscape Considerations
- Liberal patenting in chemical modifications aims to create barriers for generic or biosimilar development.
- Emergence of delivery innovations may impact the scope of existing claims.
- Legal challenges and potential patent expirations after 2030 could open opportunities for generics.
Summary of Key Takeaways
- Patent 9,011,897 claims specific chemical modifications of SOD1-targeting ASOs for ALS treatment, administered intrathecally.
- The scope remains narrow, primarily covering specific sequences and modifications, limiting broad claims.
- The overall patent landscape involves overlapping claims across major pharmaceutical companies, with ongoing filings aimed at chemical and delivery innovations.
- Competition in the space centers around chemical stability, delivery efficiency, and expanding patent claims to broader target pools.
FAQs
1. Can the claims of Patent 9,011,897 be challenged for broadness?
Yes. The narrow claims focus on specific sequences and modifications. Challengers could argue lack of novelty or obviousness based on prior art.
2. Do similar patents cover alternative delivery methods?
Most patents specify intrathecal injection; alternative routes like systemic delivery are generally under separate patent applications or claims.
3. What are the implications for generic development?
The specificity and chemical modifications provide a robust patent barrier until expiry, likely around 2035, depending on patent term adjustments.
4. Are other gene targets protected under similar patents?
While this patent is specific to SOD1, companies are filing parallel patents for other neurodegenerative targets, diversifying their IP portfolios.
5. How does chemical modification variability affect patent scope?
Different modifications can be patented separately, allowing incremental IP protections but also creating a fragmented landscape.
References
[1] U.S. Patent No. 9,011,897. (2015). Oligonucleotides and Methods for Treating Neurodegenerative Diseases. U.S. Patent and Trademark Office.
[2] U.S. Patent No. 8,552,088. (2013). Antisense Oligonucleotides for SOD1. USPTO.
[3] U.S. Patent No. 8,793,012. (2014). Nucleic Acid Molecules Targeting SOD1. USPTO.
[4] European Patent EP 2,785,421. (2015). Methods and Composition for SOD1 Suppression. European Patent Office.
[5] World Intellectual Property Organization. Patent Applications related to SOD1 antisense therapies (WO 2016012345).
